CG
TPST icon

Cutler Group’s Tempest Therapeutics TPST Stock Holding History

Cutler Group’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8
Closed -$1K – 4883
2020
Q1 		$1K Buy
+8
New +$11.7K ﹤0.01% 3808
2016
Q4 		– Hold
0
– -$1K – 7316
2016
Q3 		– Hold
0
– – – 6295

Other funds holding TPST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's TPST Position: Q1 2024 in Review

Cutler Group reduced its Tempest Therapeutics (TPST) stake by 98% in Q1 2024, selling an estimated $49.3K and leaving 16 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Cutler Group first reported a position in TPST in Q4 2015 and has held it in 10 quarters since. The position peaked at $856K in Q4 2015. 28 funds tracked by Wall St. Rank hold TPST as of Q1 2024.

  • Cutler Group held 16 shares of Tempest Therapeutics worth $0 as of Q1 2024.
  • Cutler Group sold 976 Tempest Therapeutics shares in Q1 2024, an estimated $49.3K.
  • Tempest Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #3598 holding.
  • Cutler Group first reported a position in Tempest Therapeutics in Q4 2015 and has held it in 10 quarters since.
  • Cutler Group's Tempest Therapeutics position peaked at $856K in Q4 2015.
  • 28 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.